Literature DB >> 25705639

Advances and challenges in the molecular biology and treatment of glioblastoma-is there any hope for the future?

Ignacio Veliz1, Yong Loo1, Omar Castillo1, Niki Karachaliou1, Olga Nigro1, Rafael Rosell1.   

Abstract

Malignant gliomas, such as glioblastoma multiforme (GBM), present some of the greatest challenges in the management of cancer patients worldwide. Even with aggressive surgical resections and recent advances in radiotherapy and chemotherapy, the prognosis for GBM patients remains dismal and quality of life is poor. Although new molecular pathways crucial to the biology and invasive ability of GBM are coming to light, translation of basic science achievements into clinical practice is slow. Optimal management requires a multidisciplinary approach and knowledge of potential complications arising from both disease and treatment. To help illustrate "where we are going" with GBM, we here include a detailed depiction of the molecular alterations underlying this fatal disease, as well as intensive research over the past two decades that has led to considerable advances in the understanding of basic GBM biology, pathogenesis and therapeutic approaches.

Entities:  

Keywords:  Glioblastoma; targeted therapies; temozolomide (TMZ)

Year:  2015        PMID: 25705639      PMCID: PMC4293478          DOI: 10.3978/j.issn.2305-5839.2014.10.06

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  93 in total

1.  Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target.

Authors:  Anna Saborowski; Michael Saborowski; Monika A Davare; Brian J Druker; David S Klimstra; Scott W Lowe
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-23       Impact factor: 11.205

2.  Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival.

Authors:  Peter Vajkoczy; Pjotr Knyazev; Andrea Kunkel; Hans-Holger Capelle; Sandra Behrndt; Hendrik von Tengg-Kobligk; Fabian Kiessling; Uta Eichelsbacher; Marco Essig; Tracy-Ann Read; Ralf Erber; Axel Ullrich
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

3.  A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Authors:  Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

Review 4.  Astrocyte elevated gene-1: far more than just a gene regulated in astrocytes.

Authors:  Devanand Sarkar; Luni Emdad; Seok-Geun Lee; Byoung Kwon Yoo; Zao-Zhong Su; Paul B Fisher
Journal:  Cancer Res       Date:  2009-11-10       Impact factor: 12.701

5.  A network model of a cooperative genetic landscape in brain tumors.

Authors:  Markus Bredel; Denise M Scholtens; Griffith R Harsh; Claudia Bredel; James P Chandler; Jaclyn J Renfrow; Ajay K Yadav; Hannes Vogel; Adrienne C Scheck; Robert Tibshirani; Branimir I Sikic
Journal:  JAMA       Date:  2009-07-15       Impact factor: 56.272

6.  The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas.

Authors:  Arnab Chakravarti; Gary Zhai; Yoshiyuki Suzuki; Sormeh Sarkesh; Peter M Black; Alona Muzikansky; Jay S Loeffler
Journal:  J Clin Oncol       Date:  2004-05-15       Impact factor: 44.544

7.  Moving toward molecular classification of diffuse gliomas in adults.

Authors:  Brett J Theeler; W K Alfred Yung; Gregory N Fuller; John F De Groot
Journal:  Neurology       Date:  2012-10-30       Impact factor: 9.910

8.  IDH1 R132H mutation generates a distinct phospholipid metabolite profile in glioma.

Authors:  Morteza Esmaeili; Bob C Hamans; Anna C Navis; Remco van Horssen; Tone F Bathen; Ingrid S Gribbestad; William P Leenders; Arend Heerschap
Journal:  Cancer Res       Date:  2014-07-08       Impact factor: 12.701

9.  EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing.

Authors:  Joshua M Francis; Cheng-Zhong Zhang; Cecile L Maire; Joonil Jung; Veronica E Manzo; Viktor A Adalsteinsson; Heather Homer; Sam Haidar; Brendan Blumenstiel; Chandra Sekhar Pedamallu; Azra H Ligon; J Christopher Love; Matthew Meyerson; Keith L Ligon
Journal:  Cancer Discov       Date:  2014-06-03       Impact factor: 39.397

10.  EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma.

Authors:  Qi-Wen Fan; Christine K Cheng; W Clay Gustafson; Elizabeth Charron; Petra Zipper; Robyn A Wong; Justin Chen; Jasmine Lau; Christiane Knobbe-Thomsen; Michael Weller; Natalia Jura; Guido Reifenberger; Kevan M Shokat; William A Weiss
Journal:  Cancer Cell       Date:  2013-10-14       Impact factor: 31.743

View more
  11 in total

1.  Authors' reply.

Authors:  Song Tao Timothy Cheo; Keith Hsiu Chin Lim
Journal:  Singapore Med J       Date:  2017-04       Impact factor: 1.858

2.  In Vivo Detection of EGFRvIII in Glioblastoma via Perfusion Magnetic Resonance Imaging Signature Consistent with Deep Peritumoral Infiltration: The φ-Index.

Authors:  Spyridon Bakas; Hamed Akbari; Jared Pisapia; Maria Martinez-Lage; Martin Rozycki; Saima Rathore; Nadia Dahmane; Donald M O'Rourke; Christos Davatzikos
Journal:  Clin Cancer Res       Date:  2017-04-20       Impact factor: 12.531

Review 3.  Precision diagnostics based on machine learning-derived imaging signatures.

Authors:  Christos Davatzikos; Aristeidis Sotiras; Yong Fan; Mohamad Habes; Guray Erus; Saima Rathore; Spyridon Bakas; Rhea Chitalia; Aimilia Gastounioti; Despina Kontos
Journal:  Magn Reson Imaging       Date:  2019-05-06       Impact factor: 2.546

Review 4.  Molecular and Circulating Biomarkers in Patients with Glioblastoma.

Authors:  Nadia Senhaji; Asmae Squalli Houssaini; Salma Lamrabet; Sara Louati; Sanae Bennis
Journal:  Int J Mol Sci       Date:  2022-07-05       Impact factor: 6.208

5.  From glioblastoma to endothelial cells through extracellular vesicles: messages for angiogenesis.

Authors:  Ilaria Giusti; Simona Delle Monache; Marianna Di Francesco; Patrizia Sanità; Sandra D'Ascenzo; Giovanni Luca Gravina; Claudio Festuccia; Vincenza Dolo
Journal:  Tumour Biol       Date:  2016-07-22

Review 6.  Extracellular Vesicles in Brain Tumor Progression.

Authors:  Esterina D'Asti; Shilpa Chennakrishnaiah; Tae Hoon Lee; Janusz Rak
Journal:  Cell Mol Neurobiol       Date:  2016-03-18       Impact factor: 5.046

7.  Assessing Variability in Brain Tumor Segmentation to Improve Volumetric Accuracy and Characterization of Change.

Authors:  Edgar A Rios Piedra; Ricky K Taira; Suzie El-Saden; Benjamin M Ellingson; Alex A T Bui; William Hsu
Journal:  IEEE EMBS Int Conf Biomed Health Inform       Date:  2016-04-21

8.  Differentially expressed proteins in glioblastoma multiforme identified with a nanobody-based anti-proteome approach and confirmed by OncoFinder as possible tumor-class predictive biomarker candidates.

Authors:  Ivana Jovčevska; Neja Zupanec; Žiga Urlep; Andrej Vranič; Boštjan Matos; Clara Limbaeck Stokin; Serge Muyldermans; Michael P Myers; Anton A Buzdin; Ivan Petrov; Radovan Komel
Journal:  Oncotarget       Date:  2017-07-04

9.  Glioblastoma multiforme of the optic chiasm: A rare case of common pathology.

Authors:  Kirill A Lyapichev; Amade Bregy; Adrienne Cassel; Chelsea Handfield; Jose Velazquez-Vega; Matthew D Kay; Gregory Basil; Ricardo J Komotar
Journal:  Surg Neurol Int       Date:  2016-07-07

10.  Emx2 as a novel tool to suppress glioblastoma.

Authors:  Carmen Falcone; Antonio Daga; Giampiero Leanza; Antonello Mallamaci
Journal:  Oncotarget       Date:  2016-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.